长春瑞滨联合顺铂治疗晚期非小细胞肺癌疗效观察

目的:观察长春瑞滨(盖诺)联合顺铂(NP方案)治疗晚期非小细胞肺癌(NSCLC)的疗效及毒副作用。方法:42例经病理或细胞学诊断为非小细胞肺癌患者,采用国产长春瑞滨25mg/m2,第1、8天静滴;顺铂(DDP)60～80mg/m2,第1～3天静滴,28d为1个周期。结果:CR3例,PR15例,SD16例,PD8例,总有效率(CR+PR)为42.9%。主要毒副反应为白细胞减少及胃肠反应。结论:长春瑞滨联合顺铂治疗晚期NSCLC疗效确切,毒副反应可耐受。

Objective： To observe the efficacy and toxicity of vinorelbine combined with cisplatin （NP regimen） in the treatment of advanced non-small-cell lung cancer （NSCLC）.Methods： 42 patients with advanced NSCLC were confirmed by pathology or cytology. NVB were used 25mg per centiare on days 1 and days 8： DDP were used 60 to 80 nag per centiare on days 1 to days 3, A Period includes 28 days.to evaluate the efficacy and toxicity alter 2 periods at least.Results： Complete response was observed in 3 patients and partial response was observed in 15 patients.The overall response rate was 42.9%.The main tocicity was leucopenia and vomiting.Conclusions： The results indicate NP regimen for advanced NSCLC is promise,and the toxicities are tolerable.